AtoZ-CRO
Holistic & Economic Clinical Research

A part from its breathtaking architecture and being a tourist’s delight, not many know that Eastern Europe is a popular hub for clinical research. With patients from the region willing to dedicate themselves toward healthcare activities and the low costs involved in patient recruitment, it is the prime location. Over the recent few years, healthcare organizations have turned toward solution providers to exploit the benefits offered by the region. But one name shines bright against the rest, AtoZ-CRO—a German clinical research organization that helps healthcare institutions and pharmaceuticals in conducting phase I-IV clinical studies economically. Over the past three decades, the organization has emerged as a trusted partner of sponsors, pharmaceuticals, and other healthcare institutions looking for quick patient recruitment.

Founded in 1984, AtoZ-CRO predominantly addressed the clinical research concerns of companies in Europe during its initial days, but today, it extends its services to clients across the globe by leveraging its channel partners. “We render clinical research services for clinical studies phase I-IV. The advantage of collaborating with AtoZ-CRO is our agility since we choose an apt partner based on the client organization’s needs and the services required,” mentions Dr. med. Karl Peter Klein, Managing Director, AtoZ-CRO.

The company delivers an array of services, which include planning, and initiation of clinical studies, patient recruitment and monitoring, design and implementation of CRFs, biometry & statistics, as well as pharmacovigilance. Although AtoZ-CRO has strived to deliver uniqueness through its service suite, in Dr. Klein’s opinion, a factor that differentiates the firm from its peers is the flexibility to select partners best suited for a client’s clinical needs to tailor an enterprise-specific solution, as compared to the rigidity involved with many reputed industry bigwigs.

Apart from helping clients accomplish clinical studies economically, AtoZ-CRO has also been constantly supporting its partners situated in countries like the U.S. with short-time patient recruitment. The company’s access to highly motivated individuals willing to support clinical research has consistently helped onboard patients within a short timeframe and has ensured a low dropout rate. The enthusiasm among patients belonging to Eastern Europe to dedicate themselves toward clinical studies results in lower recruitment costs as well. These abilities are perhaps the greatest advantages for a sponsor joining hands with AtoZ-CRO.

AtoZ-CRO assists in planning and initiation of clinical studies, patient recruitment and monitoring, biometry & statistics, as well as pharmacovigilance

Dr. Klein opines that Eastern Europe is highly advantageous as compared to other parts of the continent for institutions dedicated toward clinical research. The industry veteran backs his opinion and illustrates the abilities of his firm by recalling the experience of working with a biotechnology firm, one of AtoZ-CRO’s esteemed clients. The organization intended to conduct a phase-I study of individuals suffering from cancer, was challenged by a dearth of patients, and joined hands with AtoZ-CRO to accomplish its objective. Collaborating with the organization helped the client achieve its mission effortlessly and AtoZ-CRO’s agile approach was an additional benefit experienced by the biotechnology firm. The advantage of AtoZ-CRO’s location was quick patient recruitment, facilitated by its network of local monitors and investigators.

A discussion about the technical c apabilities of AtoZ-CRO is probably incomplete without a description of its approach toward Quality Management. The AtoZ-CRO GmbH Quality System is a testimony of the firm’s commitment to deliver legal compliance services of the highest quality and value to sponsors and authorities alike. Adoption of the holistic Quality System sets the framework for data protection, enables optimal resource allocation as well as monitoring and measurement of internal operations.

AtoZ-CRO’s talented resource pool comprises fifteen qualified individuals from various backgrounds. This team, highly experienced in clinical research, includes medical experts, pharmacists, biologists, life scientists, and nutritionists. The team is currently being headed by Dr. Klein, who was appointed the Managing Director of the firm in 2007 and under his tutelage, the organization has accomplished several milestones; the most noteworthy one has been bridging Eastern Europe with a large number of sponsors willing to fund clinical research activities. Amalgamation of trending technologies to accommodate the transition from a paper-based environment to virtual information sharing platforms that equips patients and sponsors with real-time data has been another highlight of Dr. Klein’s tenure so far. However, Dr. Klein states that helping multiple pharmaceuticals in the development and distribution of drugs economically has been one of the greatest triumphs of the company in its journey spanning three decades.

Although the organization has earned the trust of several partners, ideally the support of many more patrons from outside Europe would accelerate AtoZ-CRO’s efforts in being a global clinical research pioneer. The company is hopeful that it will collaborate with many non-European sponsors in the days to come and put its best foot forward to contribute toward a bright future for clinical research in the continent.